Imaging software IB Neuro™ shows high correlation with tissue analysis
A preliminary study, led by cancer researchers at Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center (BNI-SJHMC) and Imaging Biometrics LLC (IB), has validated a magnetic resonance imaging perfusion (pMRI) technology with stereotactic tissue biopsy results. Using the proprietary technology contained in IB Neuro™, an accuracy of 95.6% was obtained when distinguishing tumor from post treatment radiation effects (PTRE). This makes IB Neuro™ the only perfusion analysis product directly validated with spatially accurate tissue samples.
IB Neuro™ uses dynamic susceptibility contrast (DSC) perfusion algorithms to provide information about blood volume and blood flow in the brain. These critical perfusion parameters are valuable for detecting the growth of new tumor blood vessels (angiogenesis). This angiogenic information allows clinicians to more accurately diagnose tumor aggressiveness and potentially predict responses to anti-tumor therapies. However, this rich information has not been widely accepted due to the lack of a reliable and standardized method for use in routine clinical patients.
Researchers at BNI-SJHMC have developed a unique method of correlating imaging measurements with biopsied tumor samples, which has shown promise in validating techniques using IB NeuroTM. Directly comparing pMRI measurements with brain tumor tissue biopsy samples could result in a long awaited standardized pMRI approach. This technology can potentially lead to safer, more efficient, and more accurate diagnosis and treatment of glioma patients.
